Trial Search Results
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
The purpose of this study is to examine the effects of atezolizumab, an investigational drug, for the treatment of surgically-resected non-small cell lung cancer in humans. After screening, eligible patients will be treated with chemotherapy for up to 3 months, then randomized to either atezolizumab treatment or best supportive care for one year. The study will also evaluate the ability of a biomarker, PD-L1, to predict tumor response to atezolizumab.
Stanford is currently not accepting patients for this trial.